Basic Information
Icosavax is a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines for infectious diseases, initially focusing on life-threatening respiratory conditions. Icosavax's pipeline includes vaccine candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Icosavax, Inc.
Seattle,Washington,United States of America
15~50 people
January 01, 2017
info@icosavax.com
Enterprise Profile
Industrial Sector
Technology
Concept
Application Scenarios